Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldkamp, M. M.
Right arrow Articles by Guha, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldkamp, M. M.
Right arrow Articles by Guha, A.
[Cancer Research 61, 4425-4431, June 1, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Isotype-specific Ras·GTP-Levels Predict the Efficacy of Farnesyl Transferase Inhibitors against Human Astrocytomas Regardless of Ras Mutational Status1

Matthias M. Feldkamp, Nelson Lau, Luba Roncari and Abhijit Guha2

Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, M5G-1X8 [M. M. F., N. L., L. R., A. G.]; Samuel Lunenfeld Research Institute, Mount Sinai Hospital, M5G-1X5 [M. M. F., N. L., L. R., A. G.]; Division of Neurosurgery, Toronto Western Hospital, University Health Network, and University of Toronto, M5T-2S8 [M. M. F., A. G.]; and Department of Surgical Oncology, Ontario Cancer Institute/Princess Margaret Hospital, M5T-2S8 [A. G.], Toronto, Ontario, Canada

Previous studies have demonstrated that astrocytomas express elevated levels of activated Ras·GTP despite the absence of activating Ras mutations. Farnesyl transferase inhibitors (FTIs) exert their antitumor effect in part through inhibition of Ras-mediated signaling. SCH66336 is a potent FTI presently undergoing clinical trials in patients with solid tumors. We evaluated the efficacy of SCH66336 against a panel of eight human astrocytoma cell lines and three human astrocytoma explant xenograft models in NOD-SCID mice. SCH66336 demonstrated variable antiproliferative effects against the cell lines, with IC50 ranging from 0.6 µM to 32.3 µM. Two of the three human glioblastoma multiforme (GBM) xenografts demonstrated substantial growth inhibition in response to SCH66336, with up to 69% growth inhibition after 21 days of treatment. Drug efficacy could be accurately predicted using a combination of the H-, K-, and N-isotype-specific Ras·GTP levels. These data indicate that the absence of Ras mutations does not preclude chemotherapeutic efficacy by FTIs, that Ras is likely a major target of FTIs regardless of Ras mutational status, and that isotype-specific Ras·GTP levels are a promising marker of drug efficacy.




This article has been cited by other articles:


Home page
 BloodHome page
M. Raponi, J. E. Lancet, H. Fan, L. Dossey, G. Lee, I. Gojo, E. J. Feldman, J. Gotlib, L. E. Morris, P. L. Greenberg, et al.
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Blood, March 1, 2008; 111(5): 2589 - 2596.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
D. A. Haas-Kogan, A. Banerjee, M. Kocak, M. D. Prados, J. R. Geyer, M. Fouladi, T. McKnight, T. Y. Poussaint, A. Broniscer, S. M. Blaney, et al.
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma
Neuro-oncol, January 1, 2008; 10(3): 341 - 347.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Stupp, M. E. Hegi, M. R. Gilbert, and A. Chakravarti
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
J. Clin. Oncol., September 10, 2007; 25(26): 4127 - 4136.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. W. Kieran, R. J. Packer, A. Onar, S. M. Blaney, P. Phillips, I. F. Pollack, J. R. Geyer, S. Gururangan, A. Banerjee, S. Goldman, et al.
Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study
J. Clin. Oncol., July 20, 2007; 25(21): 3137 - 3143.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-Y. Sun, X. Liu, W. Zou, P. Yue, A. I. Marcus, and F. R. Khuri
The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells
J. Biol. Chem., June 29, 2007; 282(26): 18800 - 18809.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Kamnasaran, B. Qian, C. Hawkins, W. L. Stanford, and A. Guha
From the Cover: GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model
PNAS, May 8, 2007; 104(19): 8053 - 8058.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-H. Oh, W.-Y. Kim, J.-H. Kim, M. N. Younes, A. K. El-Naggar, J. N. Myers, M. Kies, P. Cohen, F. Khuri, W. K. Hong, et al.
Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., January 15, 2006; 12(2): 653 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
R. E. Brown and A. Law
Morphoproteomic Demonstration of Constitutive Nuclear Factor-kappaB Activation in Glioblastoma Multiforme with Genomic Correlates and Therapeutic Implications
Ann. Clin. Lab. Sci., January 1, 2006; 36(4): 421 - 426.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. D. Basso, P. Kirschmeier, and W. R. Bishop
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
J. Lipid Res., January 1, 2006; 47(1): 15 - 31.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. F. Cloughesy, J. Kuhn, H. I. Robins, L. Abrey, P. Wen, K. Fink, F. S. Lieberman, M. Mehta, S. Chang, A. Yung, et al.
Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
J. Clin. Oncol., September 20, 2005; 23(27): 6647 - 6656.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. Shannon, N. Sabha, N. Lau, D. Kamnasaran, D. H. Gutmann, and A. Guha
Pathological and Molecular Progression of Astrocytomas in a GFAP:12V-Ha-Ras Mouse Astrocytoma Model
Am. J. Pathol., September 1, 2005; 167(3): 859 - 867.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens
Development of Farnesyl Transferase Inhibitors: A Review
Oncologist, September 1, 2005; 10(8): 565 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Ren, S.-K. Tai, F. Khuri, Z. Chu, and L. Mao
Farnesyltransferase Inhibitor SCH66336 Induces Rapid Phosphorylation of Eukaryotic Translation Elongation Factor 2 in Head and Neck Squamous Cell Carcinoma Cells
Cancer Res., July 1, 2005; 65(13): 5841 - 5847.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Takada, F. R. Khuri, and B. B. Aggarwal
Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF-{kappa}B-regulated Gene Expression and Up-regulation of Apoptosis
J. Biol. Chem., June 18, 2004; 279(25): 26287 - 26299.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-H. Chun, H.-Y. Lee, K. Hassan, F. Khuri, W. K. Hong, and R. Lotan
Implication of Protein Kinase B/Akt and Bcl-2/Bcl-XL Suppression by the Farnesyl Transferase Inhibitor SCH66336 in Apoptosis Induction in Squamous Carcinoma Cells
Cancer Res., August 15, 2003; 63(16): 4796 - 4800.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z.-y. Huang, Y. Wu, S. P. Burke, and D. H. Gutmann
The 43,000 Growth-associated Protein Functions as a Negative Growth Regulator in Glioma
Cancer Res., June 1, 2003; 63(11): 2933 - 2939.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Shi, J. Gera, J.-h. Hsu, B. Van Ness, and A. Lichtenstein
Cytoreductive Effects of Farnesyl Transferase Inhibitors on Multiple Myeloma Tumor Cells
Mol. Cancer Ther., June 1, 2003; 2(6): 563 - 572.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. A. Woods, C. J. McGlade, and A. Guha
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells
Neuro-oncol, October 1, 2002; 4(4): 242 - 252.
[Abstract] [PDF]

Home page
 Neuro OncolHome page
F. F. Lang, M. R. Gilbert, V. K. Puduvalli, J. Weinberg, V. A. Levin, W.K. A. Yung, R. Sawaya, G. N. Fuller, and C. A. Conrad
Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies
Neuro-oncol, October 1, 2002; 4(4): 268 - 277.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
A. Chakravarti, A. Chakladar, M. A. Delaney, D. E. Latham, and J. S. Loeffler
The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in a RAS-dependent Manner
Cancer Res., August 1, 2002; 62(15): 4307 - 4315.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. R. Hoover, F.-X. Mahon, J. V. Melo, and G. Q. Daley
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
Blood, July 18, 2002; 100(3): 1068 - 1071.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
H. M. Fathallah-Shaykh
Darts in the Dark Cure Animal, but Not Human, Brain Tumors
Arch Neurol, May 1, 2002; 59(5): 721 - 724.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.